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Abstract Transcription levels of the non-specific N-aminolevu-
linate synthase (ALAS-N) and heme oxygenase-1 (HO-1) in the
placenta at the terminal stage of pregnancy were comparable to
those in the female adult liver and in the spleen, respectively.
Immunohistochemical studies demonstrated that both enzymes
were exclusively expressed in the trophoblast. During gestation,
transcript of ALAS-N slightly increased, while HO-1 mRNA
significantly decreased. Induced acute fetal hypoxia resulted in
an increase in ALAS-N mRNA and in a decrease in HO-1
mRNA. These findings indicate that placental heme metabolism
is influenced by the oxygen supply.
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1. Introduction
The placenta is a unique organ which transports essential
substances for fetal development to the fetus from the uterine
artery to the umbilical vein via trophoblasts. For the rapid
growth of the fetus, a huge amount of oxygen needs to be
supplied through the placenta. Though hemoproteins are
thought to be responsible for oxygen transfer from the mother
to the fetus, little is known about heme metabolism and its
possible changes in the placenta during fetal development.
Heme content is mainly controlled by its biosynthesis and
degradation [1]. The two major organs for heme biosynthesis
are the erythroid bone marrow cells and the liver [2]. Ery-
throid heme synthesis is exclusively dependent on the ery-
throid-speci¢c isoform of N-aminolevulinate synthase [3]. In
contrast, in the liver, heme content is determined by the level
of the non-speci¢c isoform of N-aminolevulinate synthase
(ALAS-N), which is the rate limiting enzyme of heme biosyn-
thesis and regulated by cytosolic free heme in a negative feed-
back manner [1^5]. It is likely that heme biosynthesis in the
placenta may also be dependent on ALAS-N. However, little
is known about its tissue-speci¢c heme synthesis in this organ.
The major site of heme degradation in adult animals is the
spleen, where a markedly elevated activity of heme oxygenase
(HO), the rate-limiting enzyme of heme catabolism, is ob-
served [6]. To date, three HO isozymes have been identi¢ed,
i.e. inducible HO-1, constitutive HO-2 and a poor heme cata-
lyst, HO-3 [7^10]. HO-1 gene is activated not only by its
substrate heme, but also by various kinds of oxidative stress
[6] yielding bilirubin IXa, an e¡ective anti-oxidant [11,12].
This information suggests that oxygen concentration may
also in£uence HO-1 gene expression in feto-placental tissues.
In fact, HO-1 has been shown to be an oxygen-regulated
protein 33 (ORP 33) [13]. Thus, hypoxic environment of fetus
[14] may in£uence the expression of HO-1 in the placenta,
resulting in an alteration in heme metabolism.
In this study, we examined developmental changes in
mRNAs of key enzymes for heme synthesis and degradation
in the rat placenta. Our ¢ndings demonstrate that both
ALAS-N and HO-1 are expressed in placenta not only in
the level of mRNA but also in that of protein. There are
also developmental changes in the expression of mRNAs for
the enzymes corresponding to heme metabolism, and these
changes occur in response to hypoxia in the fetal environment.
2. Materials and methods
2.1. Animals
Female Wistar rats from 15 to 21 days of gestation were used. They
were housed in a temperature-controlled (24‡C) room with a 12-h
light/12-h dark cycle, and were allowed free access to water and
food. Animals were sacri¢ced by decapitation under light anesthesia
with ethylether. Placenta, brain and liver from fetus, and brain, liver
and spleen from non-pregnant adult female rats were excised. They
were frozen immediately in liquid nitrogen and stored at 380‡C until
total RNA isolation. To induce hypoxia in the fetus, uterine vessels of
rats at day 19 of gestation were ligated under light anesthesia with
ethylether according to Wigglesworth’s method [15]. Animals were
sacri¢ced at 2, 3, 4 and 5 h after the ligation and the placenta was
excised as described above.
2.2. cRNA probes
cRNA probes for rat ALAS-N [16] and HO-1 [17] were transcribed
from pKRA2cA and pRHO-1, respectively, as described previously
[3,18]. Template for rat HO-2 cRNA is rat cDNA corresponding to
443^948 bp [19], which was cloned from the rat fetal brain library
using PCR and constructed into pGEM-T vector (Promega, Madison,
WI, USA). All probes for Northern blot analysis were biotin-14CTP
labeled antisense riboprobes which were prepared according to the
manufacturer’s instructions using Non-radioactive RNA Labeling
System (Life Technologies, Gaithersburg, MD, USA).
2.3. Northern blot analysis
Twenty Wg of total RNA, isolated from 3^5 placentas according to
the method of Cathara et al. [20], were applied for Northern blot
analysis as described previously [3,18]. After blotting onto a sheet
of BIODYNE A nylon membrane (Pall BioSupport Division, Pall,
Port Washington, NY, USA), samples were hybridized with cRNA
probes, treated with RNase A (1 Wg/ml), followed by washing under a
stringent condition [3,18]. Detection of mRNAs was carried out by
using PHOTOGENE Nucleic Acid Detection System (Life Technolo-
gies, Gaithersburg, MD, USA). Chemiluminescent signals were visual-
ized by exposing the membrane to X-ray ¢lms. Levels of mRNAs
were quantitated by densitometry using a BioImage Analyzer (Milli-
pore, Bedford, MA, USA).
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2.4. Immunohistochemistry
Placenta from a rat on day 19 of gestation was ¢xed by 10% neu-
tralized formalin for 24 h at room temperature, and were embedded in
para⁄n, then sliced into 4-Wm thick sections. After depara⁄nization
and rehydration, they were subjected to immunohistochemical analy-
sis. Endogenous peroxides were blocked by 3% hydrogen peroxide,
followed by incubation with primary antibodies, i.e. rabbit polyclonal
anti-rat liver HO-1, rabbit polyclonal anti-rat testis HO-2 antibody
(Stress gen Biotechnologies, Victoria), or rabbit polyclonal anti-rat
liver ALAS antibody [21], at 37‡C for 3 h. The antigen-antibody
reaction was detected using an anti-rabbit immunoglobulin and avi-
din-biotin immunoperoxidase staining kit (DAKO, Carpinteria, CA,
USA). The positive reaction was visualized by 3,3P-diaminobenzidine
staining. Untreated rabbit serum was used as a control for non-spe-
ci¢c staining. Sections were counterstained with Mayer’s hematoxylin
solution.
3. Results and discussion
3.1. Messenger RNA expression of ALAS-N and HO-1 in
various rat organs
To understand the characteristics of gene expression of
heme metabolic enzymes in the placenta, levels of mRNAs
for ALAS-N and HO-1 in the placenta at day 19 of gestation
were compared with those in other organs. Northern blot
analysis revealed that the level of transcript for ALAS-N in
the placenta was as much as 1.3-times of that in adult female
liver, which is one of the major organs for non-erythroid heme
biosynthesis in adult animals (Fig. 1). None of the feto-pla-
cental organs so far examined contains ALAS-N mRNA
higher than the placenta.
Since HO-3 is reported to be a poor heme catalyst among
three HO isozymes [8], mRNA levels for HO-1 and HO-2
were examined as measurements of gene expression for the
heme degradation. HO-1 mRNA level in the placenta was
approximately 14 times of that in the adult liver (Fig. 2). It
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Fig. 1. ALAS-N mRNA expression in various organs. Figure shown
is one of three independent experiments. a: ALAS-N mRNA level
was estimated by Northern blot analysis as described in Section 2.
Each lane contains 20 Wg of total RNA from day 19 of gestational
fetal brain, fetal liver, placenta, adult female brain and liver. Frac-
tionated RNA stained with ethidium bromide is shown in the lower
part of the panel. b: Relative amount of ALAS-N mRNA in each
sample was expressed as a percentage of that in adult female liver.
Fig. 2. HO-1 mRNA levels in various organs. Figure shown is one
of three independent experiments. a: HO-1 mRNA level was esti-
mated by Northern blot analysis as described in Section 2. Each
lane contains 20 Wg of total RNA from day 19 of gestational fetal
brain, fetal liver, placenta, adult female brain, liver and spleen.
Fractionated RNA stained with ethidium bromide is shown in the
lower part of the panel. b: Relative amount of HO-1 mRNA in
each sample was expressed as a percentage of that in adult female
spleen.
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should be noted that HO-1 mRNA level in the placenta was
substantially higher than that in the adult spleen, where the
highest activity of HO is observed among adult tissues (Fig.
2). The transcript encoding HO-2 was also expressed in the
placenta (Fig. 4a). These ¢ndings suggest that the placenta at
late gestation is highly active both in heme biosynthesis and in
its degradation.
3.2. Distribution of ALAS-N and HO proteins in the placenta
Although Northern blot analysis suggested that the placen-
ta is one of the major organs among feto-placental tissues in
the heme biosynthesis and its degradation, it is not clear
whether these transcripts are translated into proteins or not.
Furthermore, it is also unclear whether the synthesis as well as
the degradation of heme in the placenta are carried out in the
same cells or not. We therefore carried out immunohisto-
chemical studies of the placenta from a rat at day 19 of ges-
tation. Positive staining was observed for ALAS-N (Fig. 3A),
and HO-1 (Fig. 3B) and HO-2 (Fig. 3C), exclusively in troph-
oblasts, compared with the lack of signals in the section
treated with non-immune rabbit serum (Fig. 3D). Positive
staining was also observed for HO-1 (Fig. 3B) in erythroid
cells, suggesting that there were some hematopoietic progeni-
tor cells in the placenta [22]. Our observations demonstrate
that trophoblasts, where the exchange of substance between
maternal blood £ow and fetal circulation takes place, are re-
sponsible for heme metabolism in the placenta. It is thus
reasonable to assume that fetal heme is mainly degraded in
trophoblasts to excrete the end product bilirubin into the ma-
ternal circulation, since fetus expresses little amount of UDP
glucuronyl transferase during the early stage of pregnancy
[23].
3.3. Developmental changes in mRNA of ALAS-N and HOs in
the placenta
Present study indicates that the placenta is an active organ
in heme metabolic enzyme expression in day 19 feto-placental
tissues. Next we investigated the developmental changes of
mRNA of ALAS-N and HO-1 in the placenta during preg-
nancy. Fig. 4 shows changes in transcript encoding ALAS-N
from day 15, when the placenta is constructed completely, till
the birth of animals. Since the adult tissues which express the
maximal level of ALAS-N and HO-1 are liver and spleen,
respectively, each mRNA level is expressed as percent of
each maximum tissue level. The level of ALAS-N mRNA in
the placenta was lower than that in the adult liver until day 18
of gestation, when a signi¢cant induction took place, reaching
a peak, the adult liver level, at day 19. These ¢ndings dem-
onstrate that there is a developmental upregulation of heme
biosynthesis in the late gestational placenta.
In contrast to ALAS-N expression, HO-1 transcripts grad-
ually decreased from the maximum level at day 15 of gesta-
tion toward the date of birth (Fig. 4). The level of HO-1
mRNA at day 15 of gestation was 3^4 times higher than
the level in the adult spleen, then it was decreased to the adult
splenic level on the date of birth. A similar change was also
recognized in HO-2 mRNA (Fig. 4a). These ¢ndings suggest
that heme requirement in the placenta increases during the
gestation, presumably to supply a greater amount of oxygen
to fetal circulation in response to the rapidly growing fetus.
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Fig. 3. Immunohistochemistry of ALAS-N and HOs in the placenta. Placental sections from a rat at day 19 of gestation was incubated with
(A) rabbit anti-rat ALAS-N antibody, (B) rabbit anti-rat HO-1 antibody, (C) rabbit anti-rat HO-2 antibody, or (D) normal rabbit serum, fol-
lowed by immunohistochemical staining as described in Section 2 (original magni¢cation U400).
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This hypothesis is also consistent with the ¢nding that expres-
sion of ALAS-N in the placenta is restricted to trophoblasts,
the gate cells of oxygen transport from mother to fetus (Fig.
3A).
3.4. E¡ect of ligation of uterine vessels on ALAS-N and HO-1
mRNA expression in the placenta
Preceding studies indicate that heme metabolism in the pla-
centa changes from catabolism superior mid gestation stage to
biosynthesis superior late gestation stage. The physiological
meaning of this change might be attributable to increasing
oxygen demand at late gestation stage. Thus, maternal uterine
vessels of 19 days of gestation were ligated to produce an
acute hypoxic condition for the fetus, and e¡ects on gene
expression of heme metabolic enzymes were investigated
(Fig. 5). After vessel ligation, ALAS-N mRNA showed a rap-
id increase, reaching a peak at 3 h, while the HO-1 transcript
decreased to approximately 50% after 2 h of ligation. It
should be noted that the transcription of HO-1 seems to be
essentially nil in the placenta after ligation, since the half-life
of HO-1 mRNA is around 2^3 h [24]. A seemingly complete
shut-o¡ of the HO-1 gene expression by uterine vessel ligation
is in contrast to the known induction of HO-1 in the liver in
response to hypoxia [13]. Thus the oxygen regulation of HO-1
in the placenta may represent a unique tissue-speci¢c mecha-
nism.
In summary, our ¢ndings in this study demonstrate marked
gene expression of the key enzymes in heme catabolism as well
as biosynthesis in the placenta, and the possible role of hypo-
xia in regulating the expression of these genes. Our study is
also the ¢rst to indicate that fetal heme is primarily catabol-
ized in the placenta, and to de¢ne that trophoblasts are the
target cells of hypoxia, resulting in major alterations in the
placental heme metabolism.
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Fig. 4. Developmental changes in mRNA of ALAS-N and HOs in
the placenta. Figure shown is one of three independent experiments.
a: Levels of mRNA for ALAS-N, HO-1 and HO-2 in the placenta
after its complete construction (around day 15 of gestation) were
determined by Northern blot analysis. b: Relative amount of
ALAS-N (b) and HO- 1 (R) mRNA in each sample was normal-
ized with the amount detected as 28 S rRNA by ethidium bromide
staining, and was expressed as a percentage of that in adult female
liver for ALAS-N and in adult female spleen for HO-1, respectively.
Fig. 5. E¡ects of hypoxia induced by uterine vessel ligation on
ALAS-N and HO-1 mRNA expression in placenta. Uterine vessels
of rats at day 19 of gestation were ligated and animals were sacri-
¢ced at 2, 3, 4 and 5 h after ligation. ALAS-N (b) and HO-1 (R)
mRNA levels were determined by Northern blot analysis as de-
scribed in Section 2. Each level was expressed as a percentage of
the level of non-ligated control placenta.
N. Ihara et al./FEBS Letters 439 (1998) 163^167166
Acknowledgements: We are grateful to Dr. S. Shibahara (Tohoku
University, Sendai, Japan) and Dr. M. Yamamoto (Tsukuba Univer-
sity, Tsukuba, Japan) for providing us with pRHO-1 and pKRA2cA
and anti-rat liver ALAS antibody, respectively. We are also grateful
to Dr. S. Sassa (The Rockefeller University, New York, USA) for his
helpful suggestions and manuscript reviewing. This study was sup-
ported in part by a grant-in-aid for scienti¢c research from the Min-
istry of Education, Science and Culture of Japan. (to R.A., T.K. and
H.F.).
References
[1] Fujita, H. (1997) Tohoku J. Exp. Med. 183, 83^99.
[2] Kappas, A., Sassa, S., Galbraith, R.A. and Nordmann, Y. (1995)
in: The Metabolic Basis of Inherited Desease (Scriver, C.R.,
Beaudet, A.L., Sly, W.S. and Valle, D., Eds.) pp. 2103^2159,
McGraw-Hill, New York, NY.
[3] Fujita, H., Yamamoto, M., Yamagami, T., Hayashi, N. and
Sassa, S. (1991) J. Biol. Chem. 266, 17494^17502.
[4] Riddle, R.D., Yamamoto, M. and Engel, J.D. (1989) Proc. Natl.
Acad. Sci. USA 86, 792^796.
[5] Watanabe, N., Hayashi, N. and Kikuchi, G. (1983) Biochem.
Biophys. Res. Commun. 113, 377^383.
[6] Shibahra, S. (1994) in: Regulation of Heme Protein Synthesis
(Fujita, H., Ed.) pp. 103^116, AlphaMed Press, Dayton, OH.
[7] Maines, M.D., Trakshel, G.M. and Kutty, R.K. (1986) J. Biol.
Chem. 261, 411^419.
[8] McCoubrey Jr., W.K., Huang, T.J. and Maines, M.D. (1997)
Eur. J. Biochem. 247, 725^732.
[9] Trakshel, G.M., Kutty, R.K. and Maines, M.D. (1986) J. Biol.
Chem. 261, 11131^11137.
[10] Trakshel, G.M. and Maines, M.D. (1989) J. Biol. Chem. 264,
1323^1328.
[11] Stocker, R., Glazer, A.N. and Ames, B.N. (1987) Proc. Natl.
Acad. Sci. USA 84, 5918^5922.
[12] Stocker, R., Yamamoto, M., McDonagh, A.F., Glazer, A.N. and
Ames, B.N. (1987) Science (Wash. DC) 235, 1043^1046.
[13] Murphy, B.J., Laderoute, K.R., Short, S.M. and Sutherland,
R.M. (1991) Br. J. Cancer 64, 69^73.
[14] Longo, L.D. (1972) Obstet. Gynecol. Ann. 1, 103^138.
[15] Wigglesworth, J.S. (1964) J. Pathol. Bacteriol. 88, 1^13.
[16] Yamamoto, M., Kure, S., Engel, J.D. and Hiraga, K. (1988)
J. Biol. Chem. 263, 15973^15979.
[17] Shibahara, S., Muller, R., Taguchi, H. and Yoshida, T. (1985)
Proc. Natl. Acad. Sci. USA 82, 7865^7869.
[18] Fujita, H. and Sassa, S. (1989) Br. J. Haematol. 73, 557^560.
[19] Rotenberg, M.O. and Maines, M.D. (1990) J. Biol. Chem. 265,
7501^7506.
[20] Cathala, G., Savouret, J.-F., Mendez, B., West, B.L., Karin, M.,
Martial, J.A. and Baxter, J.D. (1983) DNA 2, 329^335.
[21] Yamamoto, M., Fujita, H., Watanabe, N., Hayashi, N. and Ki-
kuchi, G. (1986) Arch. Biochem. Biophys. 245, 76^83.
[22] Sassa, S. (1983) in: The Regulation of Heme Biosynthesis (Gold-
wasser, E., Ed.) pp. 359^383, Elsevier/North Holland, Harvard,
MA.
[23] Balistreri, W.F. (1987) in: Nelson Textbook of Pediatrics, 13th
Edn. (Behrman, R.E. and Vaughan, V.C., Eds.) pp. 821^824,
Saunders, Philadelphia, PA.
[24] Takahashi, K., Hara, E., Ogawa, K., Kimura, D., Fujita, H. and
Shibahara, S. (1997) J. Biochem. 121, 1162^1168.
FEBS 21080 17-11-98 Cyaan Magenta Geel Zwart
N. Ihara et al./FEBS Letters 439 (1998) 163^167 167
